Aligos Therapeutics (ALGS) Operating Leases (2019 - 2026)
Aligos Therapeutics' (ALGS) quarterly Operating Leases came in at $659000.0 in Q1 2026, down 84.55% YoY from $4.3 million in Q1 2025, and down 56.79% on a QoQ basis from $1.5 million in Q4 2025.
Aligos Therapeutics (ALGS) Operating Leases (2019 - 2026) Analysis & Trends
Aligos Therapeutics (ALGS) has 8 years of Operating Leases data on file, last reported at $659000.0 in Q1 2026.
- Quarterly Operating Leases fell 84.55% year-over-year to $659000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $659000.0 (down 84.55% YoY) and the FY2025 annual result came in at $1.5 million, down 68.2% from the prior year.
- Operating Leases slipped to $659000.0 in Q1 2026, from $1.5 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $10.9 million in Q1 2022 to a low of $659000.0 in Q1 2026.
- A 5-year average of $6.4 million and a median of $7.0 million in 2024 frame the typical range for Operating Leases.
- Annual changes were most pronounced in 2022 — Operating Leases grew 6.56% — and 2026, when it slumped 84.55%.
- Tracing ALGS's Operating Leases over 5 years: stood at $9.2 million in 2022, then dropped by 16.66% to $7.7 million in 2023, then tumbled by 37.47% to $4.8 million in 2024, then sank by 68.2% to $1.5 million in 2025, then slumped by 56.79% to $659000.0 in 2026.
- The last three Operating Leases figures came in at $659000.0 (Q1 2026), $1.5 million (Q4 2025), and $2.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Aligos Therapeutics | 67.38 Mn | 36.94 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 288,000.00 |
| Mar 31, 2026 | 659,000.00 |
| Dec 31, 2025 | 1.53 Mn |
| Sep 30, 2025 | 2.38 Mn |
| Jun 30, 2025 | 3.22 Mn |
| Mar 31, 2025 | 4.27 Mn |
| Dec 31, 2024 | 4.80 Mn |
| Sep 30, 2024 | 5.55 Mn |
| Jun 30, 2024 | 6.28 Mn |
| Mar 31, 2024 | 6.99 Mn |
| Dec 31, 2023 | 7.67 Mn |
| Sep 30, 2023 | 8.33 Mn |
| Jun 30, 2023 | 8.97 Mn |
| Mar 31, 2023 | 8.61 Mn |
| Dec 31, 2022 | 9.20 Mn |
| Sep 30, 2022 | 9.65 Mn |
| Jun 30, 2022 | 10.30 Mn |
| Mar 31, 2022 | 10.85 Mn |
| Dec 31, 2021 | 11.29 Mn |
| Sep 30, 2021 | 9.59 Mn |